Prenetics Global Limited reported Q2 2026 total revenue of $46.5 million, up approximately 3.9x year-over-year, with its flagship brand IM8 contributing $45.0 million. The company raised full-year FY2026 total revenue guidance to $220–230 million and initiated FY2027 IM8 revenue guidance of over $400 million. Management announced that consolidated Adjusted Free Cash Flow turned positive in July 2026, with expectations for continued positivity through Q3 and beyond. Additionally, Prenetics completed a $40 million share repurchase program during the quarter. Prenetics Global Limited operates in the consumer health industry, focusing on premium daily nutrition supplements under its IM8 brand.

Prenetics Global Limited announced the appointment of Caroline Levy as an independent director on its Board of Directors, effective August 17, 2026. Ms. Levy will serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, replacing Dr. Darshan Shah on those committees while Dr. Shah remains a board member. The filing also notes that Prenetics is scheduled to report its second quarter 2026 financial results on August 18, 2026. Prenetics Global Limited operates in the consumer health and wellness industry, serving as the parent company of the AI-native direct-to-consumer supplement brand IM8.

Prenetics Global Limited announced the closing of a $1 billion growth financing arrangement with General Catalyst's Customer Value Fund on July 14, 2026. The funding supports sales and marketing expansion for its IM8 business through a Customer Investment Agreement dated July 13, 2026. Investors will fund up to 70% of monthly growth spend until August 11, 2028, subject to repayment from customer collections capped at a 30% internal rate of return or a multiple between 1.035x and 1.170x. Prenetics Limited and IM8 Limited provided unconditional guarantees for the obligations. The company operates in the direct-to-consumer health sciences industry.

Prenetics Global Limited announced its unaudited financial results for the first quarter ended March 31, 2026. The company operates in the healthcare industry, providing diagnostic and health screening services.